Trophoblasts, placental cells of epithelial lineage, undergo extensive differentiation to form the cellular components of the placenta. Trophoblast progenitor cell differentiation into the multinucleated syncytiotrophoblast is a key developmental process required for placental function, where defects in syncytiotrophoblast formation and turnover associate with placental pathologies and link to poor pregnancy outcomes. The cellular and molecular processes governing syncytiotrophoblast formation are poorly understood, but require the activation of pathways that direct cell fusion. The protease, A Disintegrin and Metalloproteinase 12 (ADAM12), controls cell fusion in myoblasts and is highly expressed in the placenta localizing to multiple trophoblast populations. However, the importance of ADAM12 in regulating trophoblast fusion is unknown. Here, we describe a function for ADAM12 in regulating trophoblast fusion. Using two distinct trophoblast models of cell fusion, we show that ADAM12 is dynamically upregulated and is under the transcriptional control of protein kinase A. siRNA-directed loss of ADAM12 impedes spontaneous fusion of primary cytotrophoblasts, whereas overexpression of the secreted variant, ADAM12S, potentiates cell fusion in the Bewo trophoblast cell line. Mechanistically, both ectopic and endogenous levels of ADAM12 were shown to control trophoblast fusion through E-cadherin ectodomain shedding and remodeling of intercellular boundaries. This study describes a novel role for ADAM12 in placental development, specifically highlighting its importance in controlling the differentiation of villous cytotrophoblasts into multinucleated cellular structures. Moreover, this work identifies E-cadherin as a novel ADAM12 substrate, and highlights the significance that cell adhesion molecule ectodomain shedding has in normal development. Cell Death and Differentiation (2015) 22, 1970-1984 doi:10.1038/cdd.2015 published online 24 April 2015 In mammalian development, the placenta forms the mechanical and physiological link between maternal and fetal circulations. In rodents and higher order primates, including humans, this transfer is achieved through extensive uterine infiltration by fetal-derived cells of epithelial lineage called trophoblasts.
In mammalian development, the placenta forms the mechanical and physiological link between maternal and fetal circulations. In rodents and higher order primates, including humans, this transfer is achieved through extensive uterine infiltration by fetal-derived cells of epithelial lineage called trophoblasts. 1 Trophoblast differentiation is essential for optimal placental function, where the underlying molecular processes regulating specific functions of distinct trophoblast populations are strictly controlled. Defects in trophoblast differentiation associate with impaired placental function and directly impact fetal and maternal health. 2 Within the placenta, progenitor trophoblasts (also called villous cytotrophoblasts; vCTs) overlie a well-defined basal lamina forming an organized, mitotically active epithelial layer. vCT differentiation into an overlying multinucleated structure called the syncytiotrophoblast (synCT) is a key event in placental development. 3 The synCT, composed of millions of nuclei sharing one common cytoplasm, directs nutrient and gas exchange between maternal and fetal circulations, and serves as the primary endocrine component of the placenta. 4 Its formation, function and continued renewal depends upon vCT fusion with existing synCT, where cellular competence for fusion is initiated by activation of the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway. 5, 6 PKA directs multiple pathways important in trophoblast fusion, including the expression of the transcription factor glial cell missing 1 (GCM1). 7, 8 Coordination and propagation of the fusion signal is controlled via gap junctions, 9 ,10 cytoskeletal reorganization 11, 12 and remodeling of intercellular adhesion complexes. 13, 14 Intercellular adherens junctions, composed of members of the cadherin family of cell adhesion molecules, are dynamically regulated during trophoblast syncytialization. 13, 14 Described as important morphoregulators, 15 cadherins impact processes like cell sorting and differentiation, and thus mechanisms affecting cadherin expression or function can influence cell fusion.
A Disintegrin And Metalloproteinases (ADAMs) are Zn 2+ -dependent proteases that play diverse roles in physiological and pathological processes. Characterized structurally by an N-terminal signal sequence followed by a prodomain, a metalloproteinase domain, a disintegrin domain, a cysteine rich region, an EGF domain, a transmembrane domain and a cytoplasmic tail, 16 ADAMs affect multiple cellular processes. 17 Expressed predominately as transmembrane proteins, ADAMs function as cell surface 'sheddases', regulating the bioavailability of membrane proteins, such as growth factors and their receptors, 16 cytokines 18 and cell adhesion molecules. 19 Recently, our work has focused on the importance of ADAM12 in controlling trophoblast invasion and placental column outgrowth. 20 ADAM12, expressed as two distinct catalytically active splice variants, a full-length membranebound isoform (ADAM12L) and a truncated secreted variant (ADAM12S), is highly expressed in the placenta and localizes to invasive extravillous cytotrophoblast (EVT) subsets 20, 21 and to the synCT layer. 22 Though ADAM12's localization to the syncytium suggests that it may play a role in directing trophoblast differentiation into multinucleated structures, the importance of ADAM12 in synCT formation has not yet been tested. Functional studies in mice identify ADAM12 as a regulator in myogenesis via effects on cell fusion, 23, 24 and consistent with this, ADAM12S has been shown to direct osteoclast fusion in bone; 25 however, the molecular mechanism(s) central to these ADAM12-directed processes are poorly understood. In this study, we examine the importance of ADAM12 in regulating trophoblast fusion.
Results
ADAM12 localizes to multiple trophoblast subsets within placental villi. Previous work localized ADAM12 to EVT subsets within distal anchoring columns 20, 21 and to the synCT. 22 To confirm these findings, we re-examined ADAM12 localization in early (5-7 weeks gestation) and late (10-12 weeks gestation) first trimester placentae by immunofluorescence microscopy; the trophoblast markers hepatocyte growth factor activator inhibitor-1 (HAI-1), HLA-G and KRT7, as well as the proliferation marker Ki67 helped identify distinct trophoblast populations. 26 ADAM12 localized strongly to HLA-G + EVT columns and apically in the synCT (Figure 1a ). ADAM12 positivity was also noted in trophoblasts localized proximal to Ki67 + EVTs and stochastically to HAI-1 + vCTs; ADAM12 preferentially localized to proliferative areas within floating villi noted by strong Ki67 positivity in serial sections ( Figure 1a ). Fluorescence signal specificity was ensured by probing placental villi with an IgG1 control antibody (Supplementary Figure S1) . To examine the expression of individual ADAM12 splice variants in vivo (the antibody used above identifies both isoforms), we examined ADAM12L and ADAM12S expression in fluorescence-activated cell sorting (FACS)-purified vCTs, column EVTs and mesenchymal core cells from placental villi using CD49f and HLA-G as subtype-specific markers (Figure 1b) . 27, 28 FACS-purified cell purity was verified by qPCR analysis using the pan-trophoblast marker KRT7, the EVT marker HLA-G and the mesenchymal marker VIM; whole placental villi served as a positive control (Figure 1c) . Consistent with strong immunolocalization of ADAM12 to EVT columns, both ADAM12L and ADAM12S isoforms were expressed at higher levels in HLA-G +
CD49f
lo EVTs than in HLA-G -
hi vCTs (Figure 1d ). ADAM12S mRNA transcripts were expressed at higher levels in column EVTs compared with VIM-positive HLA-G -
-mesenchymal cells; however, ADAM12L levels did not significantly differ (Figure 1d ). Although ADAM12L was detected in placental mesenchyme and vCTs, ADAM12S expression was restricted to EVTs, with little expression detected in vCTs (Figure 1d ).
Together, these findings demonstrate that ADAM12L/S are differentially expressed among trophoblast subtypes within placental villi, and that progenitor vCTs express moderate levels of ADAM12L and low levels of truncated ADAM12S.
ADAM12 expression increases during trophoblast fusion. ADAM12's localization to the synCT suggests that its expression may be regulated during vCT fusion. To examine the temporal expression of ADAM12 during this process, vCTs from term placenta were cultured; these cells spontaneously differentiate to form multinucleated cells that resemble the synCT. 29 Fluorescence imaging of differentiating vCTs showed de novo expression of ADAM12 at 72 h, coinciding with the formation of multinucleated aggregates (Figure 2a) . At 24 h prior to cell fusion, the ADAM12 signal was undetectable (Figure 2a ). To visualize cell-cell fusion, the adherens junction molecule, E-cadherin, was probed to identify alterations in intercellular boundaries ( Figure 2a) ; at 24 h, cells retained E-cadherin borders while cells cultured for 72 h showed re-organization of E-cadherin, characterized by diffuse and diminished staining at pericellular boundaries. To assess vCT purity, immunofluorescence analysis of the lineage markers KRT7 (epithelial) and vimentin (mesenchymal) was performed; these stains revealed 490% purity (Supplementary Figure S2) .
Gene expression analysis of ADAM12L and ADAM12S showed that both isoforms increased over 72 h, with ADAM12L levels increasing fourfold and ADAM12S levels increasing over 10-fold (Figure 2b ). Immunoblotting identified a predominant 68 kDa product that likely corresponds to proteolytically processed mature ADAM12; this product peaked at 48 and 72 h of culture (Figure 2c ). Biochemical verification of vCT differentiation into multi-nucleated synCTlike structures was assessed by qPCR and immunoblot analyses probing for E-cadherin (CDH1), placental alkaline phosphatase (PLAP) and ERVW1, a gene encoding for the fusogenic retroviral envelope protein Syncytin-1. As expected, E-cadherin levels were markedly downregulated over 72 h, while PLAP levels reciprocally increased (Figures 2c and d) . ERVW1 mRNA levels transiently increased at 24 h and then subsided by 72 h (Figure 2d ).
PKA controls ADAM12 expression. The PKA pathway plays a central role in trophoblast fusion, directing the expression of crucial transcription factors (e.g. GCM1) and fusogenic genes (e.g. ERVW1). 6, 7 To this end, trophoblast differentiation into syncytial-like structures can be reproduced in vitro using the Bewo choriocarcinoma cell line in the presence of PKA agonists. We therefore examined whether ADAM12 induction during vCT differentiation could be reproduced in cAMP-differentiated Bewo cells. Visualization of untreated cells by immunofluorescence revealed that E-cadherin intercellular boundaries are retained over 72 h, while the ADAM12 signal remained absent (Figure 3a) . Seventy-two hours post cAMP treatment, profound reorganization and loss of E-cadherin boundaries are observed (Figure 3a) . Importantly, cAMP treatment results in de novo ADAM12 expression (Figure 3a) . qPCR and immunoblot analyses confirmed that ADAM12L and ADAM12S transcripts and ADAM12 protein levels increase during Bewo differentiation, where the increase in ADAM12S is greater than ADAM12L (Figure 3b ). The morphological changes in response to cAMP were characterized biochemically by qPCR analysis and immunoblotting for E-cadherin (CDH1), ERVW1 and PLAP. As expected, E-cadherin levels decreased during fusion, whereas PLAP and ERVW1 (markers of differentiation and fusion) increased (Figures 3c  and d) . Interestingly, cAMP treatment in JEG3 trophoblastic h ADAM12 directs trophoblast fusion M Aghababaei et al cells, which do not fuse in response to PKA stimulation, showed modest increases in ADAM12L and negligible increases in ADAM12S, suggesting that ADAM12S, and not ADAM12L, is the key isoform during fusion ( Figure 3e ). To test whether PKA-accelerated syncytial formation in primary trophoblasts leads to increases in ADAM12 expression above the increases measured during spontaneous fusion, vCTs were treated with PKA agonists forskolin/IBMX (F/I) over 72 h. Treatment with F/I accelerated remodeling of E-cadherin at cell boundaries at 24 h, and by 72 h, multinucleated cells were abundant comprising 470% of total cells (Figures 3f and g ). Compared with spontaneously differentiating vCTs, F/I treatment increased the proportion of multinucleated cells at 24 h (F/I median = 15.75%, inter-quartile range (IQR) = 9.2-19.3; spontaneous median = 2.1%, IQR = 0.0-6.6) and 72 h (F/I = 74.5%, IQR = 65.8-77.2; spontaneous median = 41.2%, IQR = 28.9-52.2) (Figure 3g ). The proportion of cells forming large multinucleated structures (Z10 nuclei) was also substantially greater in F/I-induced conditions (F/I median = 56.3%, IQR = 50.6-61.1; spontaneous median = 8.5%, IQR = 0.0-16.6) ( Figure 3h ). Importantly, F/I treatment increased ADAM12S and ADAM12L mRNA and ADAM12 protein levels, where the induction of ADAM12S was more pronounced than ADAM12L (Figures 3i and j) .
To examine whether PKA directly regulates ADAM12 expression in trophoblasts, Bewo cells were transiently transfected with a luciferase ADAM12 promoter reporter construct. Following transfection, ADAM12 promoter activity was examined in cells untreated or treated with cAMP. Treatment with cAMP increased ADAM12 promoter activity ( Figure 4a ). Further, cAMP treatment increased ADAM12S and ADAM12L mRNA levels, as well as ADAM12 protein, and these cAMP-directed increases were blocked by the PKA inhibitor, PKI (Figures 4b and c) . Together these findings demonstrate that PKA signaling drives ADAM12 expression during trophoblast fusion. (Figure 5d ). Consistent with this, multinuclear structures containing 6-9 or Z 10 nuclei were not observed in ADAM12-silenced cells, but were readily observed in control siRNAtransfected trophoblasts (Figure 5e ). Interestingly, these morphological changes where not reflected by alterations in expression of the fusogenic genes GCM1 or ERVW1, and the expression of the differentiation marker, CGB (βhCG), also remained unchanged (Figure 5f ). These findings suggest that ADAM12 acts independently of key fusogenic pathways, but is in itself necessary for trophoblast fusion.
ADAM12S overexpression affects intercellular boundaries and potentiates trophoblast fusion. Our observation that ADAM12S is the predominant isoform expressed during vCT and Bewo differentiation indicates a distinct role for ADAM12S in trophoblast fusion. Thus, the importance of ADAM12S was examined in Bewo cells using an ADAM12S overexpression system. Immunofluorescence imaging of ADAM12 revealed it to be perinuclear and cytoplasmic; Bewo cells stably transfected with the empty expression construct, pCMV6, served as a control (Figure 6a ). Interestingly, the assessment of E-cadherin showed that intercellular borders were altered in ADAM12S-expressing cells (Figure 6a ). Specifically, ectopic ADAM12S led to the disorganization of E-cadherin adhesions characterized by diffuse and poorly defined cell boundaries; PKA stimulation accentuated this phenotype (Figure 6b ). Although F/I treatment induced Bewo cell differentiation in control pCMV6 cells, the extent of intercellular disorganization was more pronounced in ADAM12S cells. Importantly, ADAM12S expression increased baseline and forskolin-induced cell fusion over pCMV6 controls (baseline median = 9.9%, IQR = 8.2-11.9 versus 2.8%, IQR = 1.1-4.2; F/I = 27.0%, IQR = 25.2-45.2 Figure 6c ). In unstimulated conditions, ADAM12S overexpression also increased the proportion of multinucleated cells containing 3-5 nuclei (ADAM12S median = 9.9%, IQR = 8.8-11.3; pCMV6 median = 2.8%, IQR = 1.1-4.2) and 6-9 nuclei (ADAM12S median = 1.2%, IQR = 0.0-1.7; pCMV6 median = 0.0%, IQR = 0.0-0.0) (Figure 6d) . In ADAM12S cells, F/I treatment accentuated fusion, and this was reflected by increased proportions of cells containing 6-9 nuclei (ADAM12S median = 8.9%, IQR = 7.3-12.4; pCMV6 median = 3.8%, IQR = 2.5-5.2) (Figure 6d) . In contrast to ADAM12-silenced cytotrophoblasts, ectopic ADAM12S modestly induced transcriptional programs of cell fusion (GCM1, ERVW1), but had no effect on CGB expression (Figure 6e ). These findings indicate that cell fusion machinery is enhanced in ADAM12S overexpressing cells.
Disruption of E-cadherin in ADAM12S-expressing Bewo cells suggests involvement of proteolytic shedding. To assess this possibility, we assayed conditioned media (CM) and whole cell lysates from pCMV6 and ADAM12S transfected cells for ADAM12 and E-cadherin. As expected, pro-and mature-ADAM12S protein species were detectable in CM of ADAM12S-expressing cells and undetectable in pCMV6 controls (Figure 6f ). Consistent with our previous findings, F/I treatment increased ADAM12 in CM of pCMV6 controls. Interestingly, F/I treatment increased ADAM12S expression over baseline levels in ADAM12S-transfected cells, and we reasoned that this increase may be due to the cAMP responsive element (CRE) within the CMV promoter 30 ( Figure 6f) . Importantly, ectopic ADAM12S led to an increase in soluble (85 kDa) E-cadherin (Figure 6f ). Upon F/I treatment, soluble E-cadherin was further increased, and this was observed in control and ADAM12S-expressing cells, signifying that PKA activates both ADAM12-dependent and -independent E-cadherin shedding events. Nonetheless, these observations indicate that ADAM12S promotes trophoblast fusion through ectodomain cleavage of E-cadherin.
ADAM12-directed ectodomain shedding of E-cadherin necessitates intrinsic catalytic activity. To test whether ADAM12S-directed proteolysis directs ectodomain shedding of E-cadherin, we treated Bewo cells expressing ADAM12S with either TAPI-1 or TAPI-2, two broad-spectrum metalloprotease/ADAM inhibitors. TAPI-1 and TAPI-2 treatment inhibited ADAM12S-mediated cleavage of E-cadherin, as shown by reduced soluble 85 kDa E-cadherin in CM (Figure 7a ). This was supported by immunofluorescence imaging, where ADAM12S-directed disruption of E-cadherin was rescued by TAPI-2 ( Figure 7b ). Overexpression of ADAM12S harboring a point mutation within its catalytic domain rendering it inactive (ADAM12S ΔE351Q ) 18,31 also rescued E-cadherin shedding (Figures 7c and d) . Importantly, the proportion of fused cells was significantly lower in ADAM12S ΔE351Q cells than in ADAM12S cells (Figure 7e ). Evidence that ADAM12S cleaves E-cadherin was demonstrated by an in vitro ADAM12 cleavage assay. ADAM12S, Medians are denoted by solid black lines, while top and bottom box edges denote first and third quartiles. Whiskers show the largest and smallest data point within 1.5 times the IQR. (f) qPCR analysis of GCM1, ERVW1 and CGB (βhCG) in siRNA-transfected cytotrophoblasts cultured over 48 h. Gene expression was performed in triplicate on primary cytotrophoblasts isolated from four distinct term placentae (N = 4). GAPDH was used for normalization; qPCR data presented as mean ± s.e.m. *Pr 0.05 or **Pr0.01 compared with untreated NS control ADAM12 directs trophoblast fusion M Aghababaei et al purified from whole cell lysate of ADAM12S-GFP expressing cells by GFP immunoprecipitation, was incubated with recombinant E-cadherin; in this experiment, purified ADAM12S ΔE351Q -GFP and GFP served as a controls. ADAM12S-GFP generated a 110 kDa E-cadherin cleavage product, shown by immunoblotting against E-cadherin, whereas neither ADAM12S ΔE351Q -GFP nor GFP generated cleaved E-cadherin products (Figure 7f) . Collectively, these data show that ADAM12S cleaves E-cadherin's ectodomain, disrupts intercellular boundaries and promotes trophoblast fusion.
Cytotrophoblast E-cadherin integrity is controlled by ADAM12. To test whether physiological levels of ADAM12 direct E-cadherin cleavage, we examined whether ADAM12 knockdown affects soluble E-cadherin in vCTs. CM harvested 48 h post siRNA transfection (NS and ADAM12-specific siRNA) was assayed for E-cadherin by immunoprecipitation. Soluble E-cadherin was detectable in CM of control (NS) cytotrophoblasts, while ADAM12-targeting reduced amounts of soluble E-cadherin, suggesting that as in Bewo cells, ADAM12 cleaves the extracellular domain of E-cadherin (Figure 8a ). Fluorescence imaging of ADAM12 and E-cadherin verified ADAM12 siRNA-directed knockdown, and re-affirmed that ADAM12 siRNA depletion blocks intercellular disorganization (Figure 8b ). E-cadherin transcription is dynamically downregulated in fusing vCTs.
14 To test the possibility that ADAM12 alterations might impact E-cadherin expression, we examined E-cadherin mRNA levels in control (NS) and ADAM12 siRNA-transfected vCTs. qPCR analysis showed that ADAM12 loss did not alter E-cadherin (CDH1) expression (Figure 8c ). To demonstrate that E-cadherin cleavage in fusing trophoblasts is primarily attributable to ADAM12, and not to related ADAM proteases known to cleave E-cadherin (i.e. ADAM10 and ADAM15), 32, 33 we examined the expression of these proteases. qPCR analysis of ADAM10 and ADAM15 over 72 h showed that their levels actually decreased, an observation opposite to the expression of ADAM12 (Figure 8d ). These findings suggest that ADAM12 is the dominant ADAM protease capable of cleaving E-cadherin in differentiating trophoblasts.
Lastly, we immunostained sections of first trimester placenta with antibodies targeting E-cadherin and ADAM12; visualization of trophoblast subtypes is shown by HLA-G and KRT7 labeling. Interestingly, ADAM12 positivity was observed in select E-cadherin-positive vCTs, where its signal appeared perinuclear and proximal to E-cadherin intercellular boundaries (Figure 8e) . Notably, intense ADAM12 expression was localized to vCTs fusing with overlying synCT, providing in vivo evidence that ADAM12 expression during vCT differentiation participates in E-cadherin remodeling at cell-cell boundaries (Figure 8e ).
Discussion
Here, we describe a novel role for ADAM12 in controlling trophoblast fusion. We show that suppression of ADAM12 in primary cytotrophoblasts inhibits cell fusion, whereas ectopic expression potentiates fusion by promoting intercellular remodeling and disorganization of adherens junctions. We provide evidence that ADAM12S contributes to vCT fusion through ectodomain shedding of E-cadherin. This is the first report demonstrating a functional role for ADAM12 in directing trophoblast fusion, and in addition highlights a novel ADAM12 substrate.
Cell fusion is fundamental to multiple cellular processes, including the immune response, tissue homeostasis and regeneration, and possibly cancer. 3 The molecular processes important in cell fusion have been primarily identified from studies examining intracellular vesicle fusion and viral-host cell fusion. 34 In these systems, fusogenic molecules can be grouped into three types: (i) molecules that facilitate cell-cell adhesion; (ii) molecules that directly rearrange cell lipid bilayers and promote fusion pore formation; and (iii) molecules that direct fusion pore extension and complete membrane disassembly. 3 The importance of ADAM proteins in spermegg and myoblast fusion appears to be related to their abilities to affect the initial stages of cell-cell adhesion (i.e. ADAMs may be type-1 fusion proteins). Specifically, the disintegrin domain of ADAM2 directs sperm-egg adhesion via α6β1 integrin, 35 while ADAM12-α9β1 integrin promotes myoblast fusion in muscle. 36 In our work, ADAM12 is dynamically increased in differentiating cytotrophoblasts and promotes E-cadherin shedding. This molecular process appears to be important for cell fusion because siRNA depletion of ADAM12 severely dampens E-cadherin ectodomain shedding as well as syncytial formation, and this occurs irrespective of fusogenic gene regulation (i.e. GCM1/ERVW1). In this respect, ADAM12 impacts cell adhesion as well as cell fusion, but whether it affects the initial stages of cell-cell adhesion prior to fusion or during membrane disassembly is difficult to decipher.
Whether ADAM12 functions as a bonafide sheddase or potentiates the activity of other proteases capable of cleaving E-cadherin necessitates further investigation. It was shown that ADAM12L controls MMP14 activity through an αvβ3 integrin-dependent mechanism independent of its cytoplasmic tail or catalytic activity. 37 Similarly, ADAM12S may control the activity of E-cadherin sheddases like MMP14; however, our demonstration that ADAM12's catalytic activity is required for E-cadherin shedding, combined with findings showing that ADAM12 directly cleaves several membrane-bound substrates, including the type-II cadherin VE-cadherin, 38 supports a role for direct proteolysis of E-cadherin by ADAM12.
Discrepancies exist related to ADAM12 expression within the placenta, where previous studies have localized ADAM12 to the apical membrane 20, 22, 39 and cytoplasm 22 of the synCT, as well as stochastically within vCTs. 22 Further, we 20 and others 21 have localized ADAM12 to EVTs; together these data show that ADAM12 is expressed by multiple trophoblast subtypes and imply that ADAM12 has diverse functions in placentation. In this study, FACS purification followed by gene expression analysis of ADAM12L and ADAM12S in vCTs and column EVTs clearly shows that ADAM12S is restricted to EVTs, while ADAM12L levels are less defined between these cell types. Further studies are needed to dissect the role of ADAM12L in trophoblast biology.
Our finding that ADAM12 generates a soluble E-cadherin product suggests some interesting possibilities for E-cadherin shedding in cell fusion. Firstly, the E-cadherin ectodomain may impart molecular cues required for cell fusion. This possibility is supported by recent findings showing that ADAM10-and ADAM15-cleaved E-cadherin activates multiple pathways (EGFR/IGFR), drives MMP activity and promotes tumor cell invasion; 40, 41 these pathways are also important in trophoblast fusion, highlighting a possible function for the E-cadherin ectodomain during syncytialization. 42, 43 Secondly, ADAM10-directed ectodomain shedding of E-cadherin and N-cadherin promotes β-catenin nuclear localization and activates Wnt/β-catenin signaling pathways. 32, 33 The transcription factor, GCM1, which is central in trophoblast fusion, is a downstream target of Wnt/β-catenin, suggesting that proteolytic events controlling E-cadherin cleavage and β-catenin activation may also regulate trophoblast fusion. 44 This possibility is supported by our findings that ADAM12S overexpression leads to increases in both GCM1 and ERVW1 expression, supporting the likelihood that ADAM12 regulates GCM1 through an E-cadherin-dependent mechanism. In summary, this study defines a novel role for ADAM12 in trophoblast fusion. The diverse functions of ADAM12 in placental development are beginning to be elucidated: its roles in promoting trophoblast invasion and fusion have now been defined. Notably, ADAM12S, which shows restricted expression in normal adult tissues, appears to be a key protease in placentation. Future work aimed at characterizing the precise molecular events following ADAM12-directed E-cadherin cleavage will provide needed insight into the cellular mechanisms governing trophoblast fusion and may shed light on the importance of ADAM12-directed ectodomain 
Materials and Methods
Tissues, cytotrophoblast isolation and cell culture. Human placental tissues were obtained with approval from the Research Ethics Board on the use of human subjects, University of British Columbia. All women provided informed written consent. First trimester placental tissues (N = 14) were obtained from women undergoing elective termination of pregnancy (gestational ages ranging from 5 to 12 weeks). Term placentae (N = 5) were obtained from healthy women undergoing elective Caesarian section at 38 weeks gestation. vCTs were isolated from term placental tissues using an adapted procedure derived by Kliman et al. 29 Following multiple washes in sterile ice-cold saline, 100 g of finely minced placental tissue was subjected to two 30-min digestions in a 37°C shaking incubator; the digestion cocktail medium (Invitrogen) containing 25 mM glucose, L-glutamine, 100 IU/ml penicillin/ streptomycin and supplemented with 10% FBS. For differentiation studies examining cell fusion, Bewo cells were cultured in the presence or absence of 1.0 mM 8-bromoadenosine-3' 5'-cyclic monophosphate sodium salt (8-Br-cAMP; Sigma) or 25 μM forskolin (Sigma)/100 μM IBMX (Sigma) over 72 h. In PKA inhibition experiments, 20 μM PKI (Promega, Madison, WI, USA) was pre-incubated in Bewo cultures for 1 h prior to PKI/cAMP co-treatments. The broad-spectrum metalloproteinase inhibitors, TAPI-1 (10 μM; Enzo Life Sciences, Farmingdale, NY, USA) and TAPI-2 (10 μM; Enzo Life Sciences), were added to culture media in select experiments; 0.5% DMSO was added to control cells. JEG-3 trophoblastic cells were purchased from (ATCC; Manassas, VA, USA) and were cultured in DMEM media containing 25 mM glucose, L-glutamine, antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin) and supplemented with 10% FBS.
Immunohistochemistry and immunofluorescence microscopy. Placental villi (6-12 weeks gestation; N = 10) were fixed in 2% paraformaldehyde overnight at 4°C. vCT cultures or Bewo cells were fixed in 4% paraformaldehyde for 20 min at 4°C, followed by washing and storage in PBS. Tissues were paraffinembedded and sectioned at 5 μm onto glass slides. Immunofluorescence was performed as described elsewhere. 20 Briefly, cells or placental tissues underwent antigen retrieval by heating slides in a microwave for 5 × 2 min intervals in a citrate buffer (pH 6.0). Sections were incubated with sodium borohydride for 5 min, RT, followed by Triton X-100 permeabilization for 5 min, RT. Slides were blocked in 5% normal goat serum/0.1% saponin for 1 h, RT, and incubated with combinations of the indicated antibodies overnight, 4°C; rabbit polyclonal ADAM12 (1 : 50, ProteinTech, Chicago, IL, USA), mouse monoclonal KRT7 (1 : 100, clone RCK105, Santa Cruz Biotechnologies, Dallas, TX, USA); rabbit monoclonal KRT7 Figure 1 were obtained by multiple Z-stacks (90 stacks; 0.24 μm optical sections) and subjected to iterative maximum likelihood algorithm deconvolution (ZenPro software, Oberkochen, Germany); representative reconstructed images are shown as maximum intensity projections.
FACS purification of placental cells. Placental villi single cell suspensions were generated from fresh first trimester placental specimens (N = 4) by enzymatic digestion and analyzed by flow cytometry following protocols adapted from Joshi et al. 45 and Beristain et al. 46 Briefly, placental villi were digested for 1.5 h at 37°C in Hank's Balanced Salt Solution, 750 U/ml collagenase and 250 U/ml hyaluronidase. Organoids obtained after vortexing were subjected to red blood cell lysis in 0.8% NH4Cl, further dissociation in 0.25% trypsin for 2 min, 5 mg/ml dispase with 0.1 mg/ml DNase I for 2 min, and filtered through a 40 μm mesh to obtain single cells. Contaminating immune and endothelial cells were removed from the cell admixture by EasySep immuno-magnetic bead purification (all reagents obtained from StemCell Technologies Inc, Vancouver, BC, Canada). Following magnetic bead exclusion, 2.5 × 10 6 cells were blocked with Fc receptor antibody (eBioscience, San Diego, CA, USA), and incubated with the following antibodies on ice for 30 min: anti-CD45 (clone 2D1, eBioscience), anti-CD49f-PE-Cy7 (clone GoH3, eBioscience) and anti-HLA-G-PE (clone 87G, eBioscience). Dead cells were excluded from analysis by staining with 7AAD (eBioscience). The cell surface markers CD49f and HLA-G were used to identify placental trophoblast cell populations, while CD45 was used to identify and exclude contaminating immune cells that were not completely removed by EasySep magnet purification. FACS analysis was performed using FACSDiva (BD) and FlowJo software (Tree Star, Inc. Ashland, OR, USA). Cell sorting was performed on a FACSAria (BD) into tubes containing ice-cold Hank's Balanced Salt Solution/2% FBS.
Gene expression analysis. Total RNA was prepared from placental villi or cell lines using TRIzol (Life Technologies). Total RNA was prepared from FACSsorted primary placental cell subpopulations using the PicoPure RNA Isolation Kit multiclonal Bewo cells constitutively expressing ADAM12S. Two micrograms of plasmid DNA was transfected using Lipofectamine 2000 transfection reagent (Life Technologies) according to the manufacturer's protocol. Selection began 48 h post transfection using 400 μg/ml G418 sulfate in Ham's F-12 medium; after selection, cells were maintained in medium containing 100 μg/ml G418 sulfate.
The generation of the ADAM12S catalytically inactive mutant expression construct, ADAM12S ΔE351Q , was previously described. 20 Briefly, a point mutation in the metalloproteinase domain of ADAM12S was introduced using the QuikChange PCR site directed mutagenesis kit (Agilent Technologies), where guanine (1059) was substituted to cytosine, resulting in a translated protein consisting of a glutamine (Q) at amino acid 351 instead of a glutamate (E), thus rendering the protein catalytically inactive. 18, 31 The parent pCMV6-ADAM12S construct served as the template for this reaction.
ADAM12 promoter activity was assayed using the pEZX-PG04 luciferase promoter reporter system (GeneCopoeia, Rockville, MD, USA; Cat# HPRM13238-PG04). The promoter reporter construct, containing a 1237-bp ADAM12 promoter sequence inserted upstream of the Gaussia luciferase (GLuc) and secreted alkaline phosphatase reporter genes in the pEZX-PG04 vector (pEZX-A12), was transiently transfected into Bewo cells using Lipofectamine 2000. The ADAM12 promoter fragment comprises the sequence from position − 1036 to +200 relative to the transcription start site (GeneCopoeia). The promoterless vector containing the luciferase reporter genes (pEZX-con; GeneCopoeia Cat# NEG-PG04) served as a control for these studies. After 24 h of culture, cells were treated with or without cAMP (Sigma). GLuc and secreted alkaline phosphatase activities were assayed from the conditioned medium post treatment using a Secrete-Pair Dual Luminescence assay Kit (GeneCopoeia; Cat# SPDA-D010). Luminescence was measured using Victor 3 V plate reader (Perkin Elmer, Waltham, MA, USA) and reported as the ratios of Gaussia luciferase normalized to secreted alkaline phosphatase.
Cell fusion assays. Cell fusion was quantified in cultures of primary vCTs and Bewo cells by microscopic analysis of E-cadherin at cell-cell boundaries. Briefly, fused cell proportions were calculated as the ratio of the number of nuclei in multinucleated cellular aggregates (Z3 nuclei per aggregate) divided by the number of total nuclei per field of view acquired by a × 40 objective. Cells were seeded (8 × 10 5 cells) in duplicate within 8-well chamber slides (BD Biosciences) and cultured over 72 h. Bewo cells were treated with either cAMP (1.0 mM) or forskolin (25 μM)/IBMX (100 μM) to induce cell differentiation. Cell fusion was defined as at least three nuclei surrounded by a cell membrane as identified by continuous E-cadherin immunofluorescence staining; nuclei were visualized with DAPI quantified using ImageJ software (ITCN plug-in; version 1.6). Five random images were acquired per well, and from these, fused cell proportions were calculated. Quantification of the proportion of multinucleated cell groups based on the number of nuclei per cell was calculated as described above, except data are presented as the proportion of cells containing 3-5, 6-9 or Z 10 nuclei. E-cadherin cleavage assay. Immunoprecipitated ADAM12S-GFP, ADA-M12
ΔE351Q
-GFP or GFP from stably transfected Bewo cells were combined with full-length recombinant E-cadherin N-terminally tagged with GST (GST-E-cadherin); immunoprecipitation was performed using an antibody targeting tGFP (Origene). Briefly, ADAM12S-GFP, ADAM12
-GFP or GFP immunoprecipitated protein was re-suspended in 60 μl cleavage assay buffer (20 mM TrisHCl, pH 7.4), where 20 μl of Protein A/G agarose-ADAM12S-GFP, -ADAM12
-GFP or -GFP complex were incubated with 400 ng of recombinant GST-E-cadherin in 50 μl PBS, pH 7.4 (Novus Biologicals, Oakville, ON, Canada) for 1 h at 37°C. Following incubation, cleavage reactions were stopped by adding 6 × sample buffer (containing βME), boiled for 5 min and centrifuged to collect supernatants. Samples were analyzed by SDS-PAGE followed by immunoblotting using antibodies directed against the extracellular domain of E-cadherin (Cell Signaling Technologies).
Statistical analysis. Primary cytotrophoblast and Bewo cell fusion assays are reported as median values and IQR. Quantitative PCR gene expression, promoter activities and protein densitometry are presented as mean values ± S.E.M. All calculations were carried out using GraphPad Prism software. For single comparisons, Mann-Whitney non-parametric unpaired t-tests were performed. For multiple comparisons, one-way ANOVA non-parametric Kruskal-Wallis analyses, followed by Dunn's post-test were performed. The differences were accepted as significant at Po0.05.
